About us
Out of complexity we create precision
Owkin is an AI biotech that unlocks complex biology to find the right treatment for every patient
Understanding Owkin
[
02:30
]
What we believe
Transforming drug discovery and development
Owkin was founded by Thomas Clozel, MD, a clinical research doctor and former assistant professor in clinical onco-hematology, and Gilles Wainrib, PhD, a pioneer in the field of machine learning in biology, in 2016.
We use AI to identify new drug candidates, de-risk and accelerate clinical trials, and build diagnostic solutions that improve patient outcomes.
Why work with Owkin
07
Global reach
Locations in Boston, New York, London, Paris, Nantes, Geneva and Berlin
03
Trusted by top 8 biopharmas
Strategic deals with:
Sanofi - AI drug discovery
BMS - AI drug development
MSD - AI diagnostics
Sanofi - AI drug discovery
BMS - AI drug development
MSD - AI diagnostics
#
Cutting-edge science & AI
Publications in top scientific journals like Nature Medicine, Nature Communications, and Hepatology
61
Academic partners
Across Canada, USA, France, Germany, Spain
141
KOLs
Close relationships with PIs including 141 KOLs with a mean H-index of 49
304
Well-funded
Million dollars raised from leading biopharma companies (Sanofi & BMS) and venture funds (F-Prime, Google Ventures & Bpifrance Large Ventures, among others)
